← Eichor
Condition: Secondary Aml Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Secondary Aml

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07028086Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Underg
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT03630991The Patient Cohort of the National Center for Precision Medicine in Leukemia
Phase N/A · 3 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05326919A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS
Phase 1 · 19 location(s) · Children's Oncology Group · NCT06247787Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysp
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02115295Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06928662Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803Cancer Experience Registry (CER) for Cancer Patients and Caregivers
Phase N/A · 1 location(s) · Cancer Support Community, Research and Training Institute, P · NCT02333604Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
Phase 2 · 7 location(s) · Joshua Zeidner · NCT054422163'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Venetoclax Basket Trial for High Risk Hematologic Malignancies
Phase 1 · 5 location(s) · Andrew E. Place, MD · NCT05292664L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adu
Phase 2/Phase 3 · 25 location(s) · Moleculin Biotech, Inc. · NCT06788756Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patien
Phase 1 · 22 location(s) · National Cancer Institute (NCI) · NCT05886049Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Ste
EARLY_Phase 1 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06398457Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Ne
Phase 2 · 1 location(s) · University of Washington · NCT04282187Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137643A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
Phase 1 · 3 location(s) · Aspera Biomedicines, Inc. · NCT07250646Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML
Phase 1/Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05584761Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogen
Phase 1/Phase 2 · 6 location(s) · Heinrich-Heine University, Duesseldorf · NCT05807932CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT05672147Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory
Phase 1 · 3 location(s) · Jennifer Saultz · NCT03874052
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.